ArticleFrontiers in immunology2025

Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.

Chang-Fu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.